Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders
characterized by inflammation and destruction of small- and medium-sized blood vessels …

The coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected
patients with kidney disease, causing significant challenges in disease management, kidney …

Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)−associated …

Background The 18-month efficacy of a single course of rituximab as compared with conventional
immunosuppression with cyclophosphamide followed by azathioprine in patients with …

Human Parvovirus B19 (PV B19) is one of the several recently described ‘emerging viruses’
and has been identified as the etiological agent of ‘fifth disease’ in childhood. Human PV …

Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 …

Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA)
for remission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are …

The BK polyomavirus (BKV) infects most of the human population, but clinically relevant
infections are mostly limited to individuals who are immunosuppressed. In transplant recipients, …

Results Risk for BKVAN was greater among ABO-incompatible than HLA-incompatible patients
(17.7% versus 5.9%; P= 0.008). Of BKVAN cases, 42% were subclinical, diagnosed by …

There continues to be rapid advancement in our understanding of the pathogenesis of
immune-mediated kidney disease. This progress has culminated in the development of multiple …